TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

Daily Photo Galleries

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Beacons track shoppers’ smartphones amid retailers’ aisles
  2. 8 Western Pennsylvania hospitals penalized over infections
  3. Nonprofit hospitals in Western Pa. feel pain in finances despite Affordable Care Act
  4. Hospital finances still crying ‘ouch’
  5. Online price battle heats up with intraday price fluctuations
  6. Ford expands air bag recall across U.S.
  7. Harmar developer sells 15 hotels in Western Pa., West Virginia
  8. Stock market makes biggest gain in 3 years
  9. FedEx to buy product-return firm Genco in e-commerce push
  10. Forward Township road to gas well waits for repairs
  11. Thread of East Liberty morphs bottles into ‘authentic’ products
Subscribe today! Click here for our subscription offers.